These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 15474337)
1. Angiogenesis in colorectal cancer: therapeutic implications and future directions. Allen J; Bergsland EK Hematol Oncol Clin North Am; 2004 Oct; 18(5):1087-119, ix. PubMed ID: 15474337 [TBL] [Abstract][Full Text] [Related]
2. Angiogenesis in colorectal cancer: prognostic and therapeutic implications. Giatromanolaki A; Sivridis E; Koukourakis MI Am J Clin Oncol; 2006 Aug; 29(4):408-17. PubMed ID: 16891872 [TBL] [Abstract][Full Text] [Related]
3. Integration of anti-vascular endothelial growth factor therapies with cytotoxic chemotherapy in the treatment of colorectal cancer. Oliveira SC; Machado KK; Sabbaga J; Hoff PM Cancer J; 2010; 16(3):220-5. PubMed ID: 20526100 [TBL] [Abstract][Full Text] [Related]
4. The present and future of angiogenesis-directed treatments of colorectal cancer. O'Dwyer PJ Oncologist; 2006 Oct; 11(9):992-8. PubMed ID: 17030640 [TBL] [Abstract][Full Text] [Related]
5. [Anti-angiogenic treatment is effective for treating metastatic colorectal cancers]. Bono P; Joensuu H Duodecim; 2004; 120(3):261-2. PubMed ID: 15061003 [No Abstract] [Full Text] [Related]
6. Anti-VEGF therapy: a new approach to colorectal cancer therapy. Carrato A; Gallego-Plazas J; Guillen-Ponce C Expert Rev Anticancer Ther; 2006 Oct; 6(10):1385-96. PubMed ID: 17069524 [TBL] [Abstract][Full Text] [Related]
7. Angiogenesis as a target in colorectal cancer therapy. Introduction. Lenz HJ Semin Oncol; 2004 Dec; 31(6 Suppl 17):1-2. PubMed ID: 15696023 [No Abstract] [Full Text] [Related]
8. Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy. Fantini MC; Becker C; Neurath MF Expert Rev Anticancer Ther; 2005 Aug; 5(4):681-94. PubMed ID: 16111468 [TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic therapy for cancer: an update. Shojaei F; Ferrara N Cancer J; 2007; 13(6):345-8. PubMed ID: 18032969 [TBL] [Abstract][Full Text] [Related]
10. Angiogenesis and hypoxic factors in colorectal cancer. Rasheed S; McDonald PJ; Northover JM; Guenther T Pathol Res Pract; 2008; 204(7):501-10. PubMed ID: 18541387 [TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic therapy at a crossroads: clinical trial results and future directions. Ellis LM J Clin Oncol; 2003 Dec; 21(23 Suppl):281s-283s. PubMed ID: 14645411 [No Abstract] [Full Text] [Related]
12. VEGF-targeted therapy: therapeutic potential and recent advances. Rosen LS Oncologist; 2005; 10(6):382-91. PubMed ID: 15967832 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic approaches of angiogenesis inhibition: are we tackling the problem at the right level? Griffioen AW Trends Cardiovasc Med; 2007 Jul; 17(5):171-6. PubMed ID: 17574125 [TBL] [Abstract][Full Text] [Related]
14. Angiogenesis inhibition in non-GIST soft tissue sarcomas. Sleijfer S; van der Graaf WT; Blay JY Oncologist; 2008 Nov; 13(11):1193-200. PubMed ID: 18987047 [TBL] [Abstract][Full Text] [Related]
15. Tumour-associated angiogenesis in human colorectal cancer. Rmali KA; Puntis MC; Jiang WG Colorectal Dis; 2007 Jan; 9(1):3-14. PubMed ID: 17181841 [TBL] [Abstract][Full Text] [Related]
19. Fumagillin inhibits colorectal cancer growth and metastasis in mice: in vivo and in vitro study of anti-angiogenesis. Hou L; Mori D; Takase Y; Meihua P; Kai K; Tokunaga O Pathol Int; 2009 Jul; 59(7):448-61. PubMed ID: 19563408 [TBL] [Abstract][Full Text] [Related]